Other languages OptiNose, Inc.

Equities

OPTN

US68404V1008

Real-time Estimate Cboe BZX Other stock markets 10:50:37 2024-05-14 EDT			5-day change	1st Jan Change
1.085 ^USD	-7.26%		+6.79%	-14.74%

01:12pm	Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	MT
05-09	OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	05-09
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	04-25
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	04-25
Sector Update: Health Care Stocks Steady Premarket Monday	03-18
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	03-15
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	03-14
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	03-07
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	01-18
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	12-06
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	12-06
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023	11-09
OptiNose Raises Full-Year 2023 Xhance Net Revenue Outlook	23-08-10
OptiNose, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
OptiNose, Inc. Approves Board Changes	23-06-13
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Optinose, Inc. Provides Revenue Guidance for Full Year of 2023	23-05-11
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages OptiNose, Inc.

Equities

OPTN

US68404V1008

Other languages

Filters